TRex Bio, Inc. (TRXB)
| Market Cap | 384.09M |
| Revenue (ttm) | n/a |
| Net Income | -46.39M |
| EPS | -10.48 |
| Shares Out | 26.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,669 |
| Open | 14.17 |
| Previous Close | 14.16 |
| Day's Range | 14.00 - 14.40 |
| 52-Week Range | 13.21 - 15.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About TRXB
TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The company’s product pipeline focuses on augmenting tissue Tregs to address critical treatment gaps and offers TRB-061, a phase 1 trial TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balanc... [Read more]
Financial Performance
Financial StatementsNews
TRexBio Announces Closing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and de...
Opening Day: Biotech duo Retension, TRex Bio come public
Two new biotech names began trading last week, with Retension Pharmaceuticals and TRex Bio making their market debuts on October 9. Retension enters the public markets with a focus on…
TRex Bio opens at $13.50, IPO priced at $14 per share
TRex Bio (TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, priced 8.333M shares at $14.00. The deal priced ...
TRex Bio indicated to open at $13.90, IPO priced at $14
TRex Bio (TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, priced 8.333M shares at $14.00. The deal priced ...
TRex Bio indicated to open at $14.05, IPO priced at $14
10:58 EDT TRex Bio (TRXB) indicated to open at $14.05, IPO priced at $14
TRex Bio indicated to open at $14.50, IPO priced at $14
TRex Bio (TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, priced 8.333M shares at $14.00. The deal priced ...
TRex Bio 8.333M share IPO priced at $14.00
The deal priced at the low-end of the $14.00-$16.00 range. JPMorgan, Evercore ISI, Cantor Fitzgerald, Stifel and Wedbush acted as joint book running managers for the offering. Published first on…
TRexBio Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and de...
Biotech IPOs Charge Ahead as Tech Deals Stall
TRex Bio and Retension Pharmaceuticals are set to continue the industry's public debut rebound.
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
Autoimmune and inflammatory diseases biotech TRex Bio files for a $100 million IPO
TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
TRex Bio IPO Registration Document (S-1)
TRex Bio has filed to go public with an IPO on the NASDAQ